Objectives-To compare the tolerance, efficacy, and pharmokinetics of amphotericin deoxycholate (Fungizone) prepared in a parenteral fat emulsion (Intralipid 20%) or glucose in HIV patients with candidiasis.
Introduction
Amphotericin remains the standard treatment of the main systemic mycoses.' In patients infected with HIV fungal infections such as candidiasis are very frequent and aspergillosis is increasing.`Although azole compounds such as ketoconazole, fluconazole, or itraconazole are widely used, incomplete response or failures of these treatments or decreased susceptibility of yeasts are increasing.-" In these situations amphotericin remains the ultimate recourse. However, toxicity is the main limitation of amphotericin. Indeed, infusion related toxicity is very frequent (up to 80% of cases) and includes chills, fever, and nausea, nephrotoxicitv being the most severe limiting factor. ' Other side effects, such as cardiac arrhythmia, are rare.
Amphotericin is a lipophilic drug that binds to sterols and intercalates among lipid bilayers. These properties suggest that amphotericin should be suitable for use with a lipid based delivery system. Indeed, its incorporation with or use in association with liposomes or lipid complexes reduces toxicity such that the therapeutic index is increased." 9 Kirsh et al reported that mixing the parenteral lipid emulsion Intralipid with amphotericin greatly reduces amphotericin related toxicity both in vitro and in vivo."' Since in routine practice these two compounds are widelv given together (but through different catheters) we decided to prepare amphotericin directlv in the lipid emulsion. We report a randomised clinical trial comparing the tolerance and efficacy of amphotericin deoxycholate (Fungizone) prepared either in Intralipid 200o or in glucose in HIV patients with candidiasis. The pharmacokinetics of these two formulations were also investigated.
Patients and methods
Patients were eligible for the study if they were aged 18 or over, infected with HIV, and had oral candidiasis. Patients were excluded if they had oesophagitis, oral Kaposi's sarcoma, known intolerance of amphotericin, pancreatitis, hyperlipidaemia, or a serum creatinine concentration above 115 [&mol/l. All eligible patients gave signed informed consent. The protocol was accepted by the local ethics committee. All patients included in the study were hospitalised in our medical unit.
Treatment-Amphotericin deoxycholate was dissolved either in 500 glucose at a final concentration of 1 6 g amphotericin/l (amphotericin-glucose) or in parenteral fat emulsion (Intralipid 20%) at a final concentration of 2 g amphotericin/l (amphotericin-fat emulsion). Whatever the preparation, amphotericin was given as a one hour infusion of 1 mg/kg/dav on four consecutive days. ' Assessment of tolerance-Clinical tolerance was monitored by using a standard data form. Sweating, chills, fever (defined as a temperature above 37-5°C and rise of more than 1°C during the infusion), nausea, pulse rate, and systolic and diastolic blood pressure were recorded at the beginning, middle, and end of the infusion and one hour afterwards. Mean blood pressure was calculated as follows: mean blood pressure= (diastolic blood pressure+(systolic blood pressurediastolic blood pressure)/3). At Canidda albia(cns 9 10 Fungal strain1 Other All the amphotericin-fat emulsion infusions were given without serious problem whereas four amphotericin-glucose treatments were stopped. Two patients had shaking chills during the first two amphotericinglucose infusions and three patients had a striking increase in creatinine concentration (>159 timol/l) on day 3 (one of whom also had chills). All Triglyceride concentrations at day 0 and day 5 were not appreciably different in the two groups (1-4 (SD 0 6) and 1-9 (0-6) mmol/l in the amphotericin-glucose group; 1-6 (0-8) and 1-5 (0 7) mmol/l in the amphotericin-fat emulsion group). Serum cholesterol concentrations also were very similar in the two groups at entry and day 5 (3-6 (1-6) and 3-3 (0 8) mmol/l in the amphotericin-glucose group; 3-7 (1-5) and [3] [4] [5] [6] [7] (0-7) mmol/l in the amphotericin-fat emulsion group). Platelet and white cell counts, haemoglobin concentration, and serum aminotransferase, y-glutamyltransferase, lipase, and amylase activities were not appreciably different in the two groups at entry and did not change after completion of either amphotericin treatment (not shown).
Applying our clinical score of oral candidiasis showed the two groups to be comparable ( glucose group (p=038; Mann-Whitney U test)). Only two patients in each group had a sterile swab at the completion of treatment, including a patient in the amphotericin-fat emulsion group whose swab at day 1 had grown Candida tropicalis. Only one patient given amphotericin-fat emulsion had Torulopsis glabrata isolated at day 5; in all the other patients C albicans was isolated at both day 1 and day 5.
Amphotericin concentrations at trough, peak, and 12 hours after the daily infusion and at day 5 (last trough) were available for nine patients in each group (figure). There were significant differences in each of these three concentrations between treatments (p= 0-01 for peak and 12 hour concentrations; p=0 0024 for trough concentrations (analysis of variance on repeated measures)). The area under the curve was greater for amphotericin-glucose than for amphotericin-fat emulsion (table IV) . Total body clearance on the fourth day of treatment and the volume of initial distribution were significantly higher with amphotericin-fat emulsion than with amphotericin-glucose whereas the volume of distribution at steady state (day 4) was slightly higher with amphotericin-fat emulsion (NS; table IV). The half life at day 4 was similar with the two preparations. The three haemodynamic measurements were done at end of each infusion.
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Discussion
The main finding of our study was that the combination of amphotericin deoxycholate with a parenteral lipid emulsion is much better tolerated than amphotericin prepared in glucose. Indeed, in this study clinical side effects were fourfold to 16-fold less frequent with amphotericin-fat emulsion than with amphotericin-glucose. There were no differences in blood pressure or pulse rate between the two treatment groups.24 Moreover, renal impairment occurred in seven of the 11 patients who received amphotericinglucose compared with only one of the 11 who received amphotericin-fat emulsion. There was a fall in magnesium values in serum and erythrocytes in patients given amphotericin-glucose but not in patients given amphotericin-fat emulsion.
Experience suggests that a prolonged duration of infusion should result in fewer side effects associated with infusion. Several case reports and one randomised study, however, did not confirm this with respect to amphotericin.1 91"21242628 Furthermore, the toxicity of amphotericin-glucose observed in this study was similar to that usually recorded.' 12 We expected a very low incidence of toxicity related to the parenteral fat emulsion itself, given the small volume infused. Indeed, although nausea could be related to She fat emulsion, no increase in hepatic or pancreatic enzyme activities was observed.3637
Amphotericin is easy to prepare in parenteral fat emulsion and is chemically stable,2" cost effective, and well tolerated at a dose of 1 mg/kg/day for four consecutive days. However, further studies are warranted to investigate the tolerance of this mixture over a longer period of treatment.
The pharmacokinetic analysis of amphotericin was based on only three samples per day, and plainly our results with respect to amphotericin-glucose were very similar to those previously reported.' 13 3 3839 Conversely, the pharmacokinetics of amphotericin were modified when the drug was prepared and infused with parenteral fat emulsion. Indeed, all calculated parameters indicated that the diffusion of amphotericin-fat emulsion was greater than the diffusion of amphotericin-glucose. It is of particular interest that the volume of initial distribution of amphotericin-fat emulsion was twice that of amphotericin-glucose whereas the difference was not so great for the volume of distribution at steady state. This could indicate that the diffusion of amphotericin-fat emulsion is much more rapid than the diffusion of amphotericin-glucose. This could have clinical implications for the treatment of tissue infections.
We did not set out to compare the relative efficacy of amphotericin-glucose and amphotericin-fat emulsion on mucosal candidiasis in patients infected with HIV. Nevertheless, we note that the reduction in the clinical score of candidiasis was similar with both treatments. This supports the argument that egg lecithins (a major component of parenteral fat emulsion) do not alter the bioactivity of amphotericin4" and confirms in vitro4' and in vivo experimental data on both candidal and cryptococcal infections2041 (V Joly, L Saint-Julien, C Carbon, P Yeni, paper presented to 31st interscience conference on antimicrobial agents and chemotherapy, Chicago, 29 September to 2 October, 1991 (abstract 578)). More importantly, a pilot study of amphotericin-fat emulsion in our institution in patients with neutropenia showed that this formulation is effective against candidaemias. Similarly, we have recorded cure of candidal oesophagitis in patients with HIV.
Conclusion
We conclude that the clinical and renal tolerance of amphotericin is dramatically improved when the drug is prepared and infused in parenteral fat emulsion. This simple and cost effective preparation of amphotericin avoids the usual need for escalating doses. In addition, its efficacy in candidal infection is similar to that of conventional amphotericin at the same dosage.
These results prepare the way for further controlled and comparative studies of amphotericin-fat emulsion in different clinical settings. For example, investigations could be done to shorten antifungal treatment by giving the full dose at once, to increase the daily dose of amphotericin, or to lengthen the duration of amphotericin treatment.
Finally, the respective benefits, limits, and indications for amphotericin-glucose, amphotericin-fat emulsion, and the new liposomal formulations of amphotericin remain to be investigated. Directorate The benefits of supplementary nutritional support in patients with femoral neck fracture have been reported,67 and there is evidence that undernutrition may be a predisposing factor in pressure sore development.8 However, the contribution of pre-existing specific nutritional deficiencies to the risk of pressure sore development has not been studied.
Zinc is an essential element which has a crucial role in immunity and healing and for which interactions with other vitamins have been described.9 Both topical and oral zinc supplementation have a beneficial effect on wound healing in zinc depleted subjects.'" Vitamin C has also been shown to promote wound healing and may have a role in immunological regulation.9 Elderly people are particularly at risk from both nutritional deficiencies and depressed immunity, and studies in this hospital have shown a high prevalence of zinc" and vitamin'2 depletion in elderly inpatients.
This study was undertaken to assess the contribution of nutritional status to the development of pressure sores in elderly patients with femoral neck fractures.
Subjects and methods
Twenty one unselected patients aged 75 or more admitted to the orthopaedic unit with a diagnosis of femoral neck fracture were invited to participate in the study, which was approved by the local clinical research (ethics) committee. Written informed consent was obtained from all patients or their next of kin. Pressure sores were defined as a full thickness epidermal break over a pressure bearing surface.
A preoperative fasting blood sample was obtained at 8-9 am on the day after admission for assay of various biochemical nutritional indices, including plasma and polymorphonuclear leucocyte zinc; plasma albumin BMJ VOLUME 305 17 OCTOBER 1992 925
